Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Nowakowski GS, Yoon DH, Peters A, Mondello P, Joffe E, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Huang D, Waltl EE, Winderlich M, Kurukulasuriya NC, Ambarkhane S, Hess G, Salles G. Nowakowski GS, et al. Among authors: waltl ee. Clin Cancer Res. 2022 Sep 15;28(18):4003-4017. doi: 10.1158/1078-0432.CCR-21-3648. Clin Cancer Res. 2022. PMID: 35674661 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 36164050
Fish-derived low molecular weight components modify bronchial epithelial barrier properties and release of pro-inflammatory cytokines.
Kalic T, Ellinger I, Kamath SD, Palladino C, Mayr V, Tscheppe A, Ruethers T, Waltl EE, Niederberger V, Lengger N, Radauer C, Hafner C, Lopata AL, Bublin M, Breiteneder H. Kalic T, et al. Among authors: waltl ee. Mol Immunol. 2019 Aug;112:140-150. doi: 10.1016/j.molimm.2019.04.029. Epub 2019 May 15. Mol Immunol. 2019. PMID: 31102986 Free PMC article.
Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response.
Eckl-Dorna J, Weber M, Stanek V, Linhart B, Ristl R, Waltl EE, Villazala-Merino S, Hummel A, Focke-Tejkl M, Froeschel R, Neubauer A, Henning R, Perkmann T, Valenta R, Niederberger V. Eckl-Dorna J, et al. Among authors: waltl ee. EBioMedicine. 2019 Dec;50:421-432. doi: 10.1016/j.ebiom.2019.11.006. Epub 2019 Nov 28. EBioMedicine. 2019. PMID: 31786130 Free PMC article.
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma.
Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. Nowakowski GS, et al. Among authors: waltl ee. Ann Hematol. 2023 Sep;102(9):2643-2644. doi: 10.1007/s00277-023-05321-3. Ann Hematol. 2023. PMID: 37432417 Free PMC article. No abstract available.
12 results